Dabigatran is a direct oral anticoagulant (DOAC) that helps prevent blood clots from forming in the body. It is frequently prescribed to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and is also indicated for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).

Rivaroxaban is a direct oral anticoagulant (DOAC) that effectively thins the blood to prevent and treat potentially dangerous blood clots. It is widely prescribed to lower the risk of stroke in patients with nonvalvular atrial fibrillation and to treat deep vein thrombosis (DVT) and pulmonary embolism (PE).

Apixaban is a direct oral anticoagulant (DOAC) used to prevent and treat blood clots. It is highly effective in reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and is also used for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).